聯合治療 (UTHR) 2026 年第三季法說會：Tyvaso 營收創新高，吸入劑 NDA 延後

重點提要

• United Therapeutics (NASDAQ: UTHR) 公布 2026 年第三季總營收達 8.33 億美元，創下歷史新高；旗艦藥物 Tyvaso 營收亦創下 5.04 億美元的新高紀錄，主要受惠於潛在需求強勁與季增成長。
• 管理層將 Tyvaso 的亮眼表現歸因於轉診量與初始用藥人數增加、劑量提升、醫師參與度更高以及每月一致的高效執行力。庫存與季節性因素並非主要驅動因素。
• 該公司 10 月份接獲 United Therapeutics 產品的轉診量突破 1,000 宗，創下單月歷史新高。管理層預期擴建後的銷售團隊將在 2026 年第四季及 2027 年做出更顯著的貢獻。
• 在與美國食品藥物管理局 (FDA) 討論後需補充足夠數據，軟霧吸入劑的新藥申請 (NDA) 預計延至 2027 年提交，而非原訂的 2026 年底。
• 口服 ralinepag 用於治療肺動脈高壓 (PAH) 目前仍處於 FDA 審查階段，PDUFA 目標決定日期為 2027 年 6 月 24 日。原料藥 (API) 供應商的合規狀態屬於法規風險，但相關補救與應變計畫已在進行中。
• United Therapeutics 目前擁有 14 項開發計畫，並表示其特發性肺纖維化 (IPF)、進行性肺纖維化 (PPF) 和慢性阻塞性肺病相關肺高壓 (PH-COPD) 的目標受眾在美國合計約有 100 萬名患者。

關鍵財務數據

業務與營運表現

Tyvaso 是主要的商業成長驅動力。管理層指出，在肺動脈高壓與間質性肺病相關肺高壓 (PH-ILD) 領域，初始用藥、轉診量、患者需求、劑量及醫師參與度均持續增強。

該公司表示本季並無顯著的庫存或季節性效益；相反地，業績反映了每月更穩定一致的商業執行力。擴建後的銷售團隊約在 9 月中旬開始帶動轉診量出現轉折拐點，但管理層表示其對第三季營收貢獻有限，預計在第四季及 2027 年會更為明顯。

高劑量 Tyvaso DPI 藥盒亦對營收與患者留存率提供支撐。管理層表示，在大劑量組合包推出後開始使用 Tyvaso DPI 的患者中，約有三分之一達到較高劑量，該比例約為以往的兩倍。

在與 Liquidia 達成和解後，United Therapeutics 預計現有患者轉用 Tyvaso DPI 的速度將保持溫和。管理層強調，PH-ILD 更大的市場機遇在於提高醫師認知度、識別符合條件的患者並開立新處方。該公司表示，該和解協定禁止競品在 PH-ILD 領域進行推廣，並禁止鼓勵仿單外使用 (off-label use)。

除了 Tyvaso，United Therapeutics 正在開發噴霧劑、乾粉療法、軟霧吸入劑、每日一次藥物及複方產品。管理層將用於 IPF 的噴霧型 Tyvaso 以及用於 PAH 的 ralinepag 視為潛在的主要成長驅動力，惟仍需獲得法規批准與成功商業化。

該公司還在繼續致力於人工製造器官替代方案的開發，管理層將其視為獨立的長期成長平台。

管理層指引

United Therapeutics 目前預計將軟霧吸入劑的 NDA 延至 2027 年提交，而非先前規劃的 2026 年底。管理層表示 FDA 並未要求新增工作類別，但補充足夠數據需要更多時間。更新後的申報時間表目前正與開發夥伴共同制定中。

管理層預計，擴大銷售團隊與 PH-ILD 和解帶來的轉診動能將在未來幾週及 2027 年初更加顯現。該公司預期進入 2027 年時將具備比進入 2026 年時更為強勁的商業動能。

針對吸入型 ralinepag，該公司正在進行提交新藥臨床試驗申請 (IND) 的準備工作，並計劃在健康志願者中進行一期臨床研究。該研究預計將引導後續的註冊試驗計畫，首要針對 PH-ILD，隨後緊接著針對 IPF 和 PPF。

風險與關注焦點

• 由於公司需要在 FDA 申報策略討論期間補充足夠的數據，軟霧吸入劑的申請已延遲至 2027 年。
• 口服 ralinepag 的原料藥 (API) 供應商在接受稽查後被列為「待採取官方行動」(OAI) 合規狀態。United Therapeutics 正在協助進行改善措施，並推進替代方案，以降低對 2027 年 6 月 24 日 PDUFA 日期的潛在風險。
• 擬議的口服三合一複方產品無法僅憑已完成的生物同等性研究進行申報。管理層正在評估 FDA 可能接受的其他替代開發路徑。
• 由於和解協定並未要求現有患者進行轉換，預計短期內從競品吸入劑轉用 Tyvaso DPI 的數量將維持溫和。
• 在 PH-COPD、PH-ILD、IPF 及 PPF 的開發計畫仍面臨臨床與法規風險。管理層表示，計畫中的吸入型 ralinepag 適應症將需要進行關鍵的安全性和有效性研究。

分析師問答環節亮點

Tyvaso 發展動能：管理層表示，在與 Liquidia 達成和解前，轉診力道就已在改善。PH-ILD 的進一步拐點可能會在 2026 年底和 2027 年初出現，但主要的機遇仍是新開立處方，而非強制患者轉用。

軟霧吸入劑延遲：與 FDA 的討論導致需要補充足夠數據，而非重新設計的開發要求。管理層將該問題主要歸因於所需的時間前置期。

Ralinepag 供應風險：公司仍專注於在 PDUFA 日期前解決其原料藥 (API) 供應商的合規狀態。糾正措施資訊已提交給 FDA，雙方保持對話，且應變計畫正同步推進。

Ralinepag 經濟效益：United Therapeutics 表示，買斷 Arena 權利金的決定反映了對口服 ralinepag 及針對多種肺部適應症的規劃乾粉劑型的信心。公司將該交易形容為對資本的擇機運用，但未在電話會議中提供估值細節。

PH-COPD 開發狀況：管理層表示，吸入型 treprostinil 可透過針對更多通氣的肺部區域來減少通氣/灌流不均 (ventilation-perfusion mismatch)。第二期計畫已獲得 IND 許可，且公司已完善入組條件，以優化研究受試群體並降低開發風險。

法說會逐字稿全文

---

完整財報電話會議逐字稿

管理層陳述

Operator

Good morning, and welcome to the United Therapeutics Corporation Third Quarter 2026 Corporate Update. My name is Christa, and I will be your conference operator today. [Operator Instructions] Please note that this call is being recorded. I will now turn the webcast over to Harrison Silvers, Investor Relations at United Therapeutics.

Harrison Silvers

Thank you, Christa. Good morning, everyone. It is my pleasure to welcome you to the United Therapeutics Corporation Third Quarter 2026 Corporate Update Webcast. Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q, contain additional information on these risks and uncertainties.

We assume no obligation to update forward-looking statements. Today's remarks may discuss the progress and results of clinical trials or other developments with respect to our products. These remarks are intended solely to educate investors and are not intended to serve as the basis for medical decision-making or to suggest that any products are safe and effective for any unapproved or investigational uses. Full prescribing information for the products is available on our website.

Accompanying me on today's call are Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer; Michael Benkowitz, our President and Chief Operating Officer; James Edgemond, our Chief Financial Officer and Treasurer; Dr. Leigh Peterson, our Executive Vice President of Product Development and Zeno Transplantation; and Pat Poisson, our Executive Vice President of Strategic Development.

Note that James Edgemond and I will participate in a fireside chat and one-on-one sessions at the UBS Global Biopharma Conference and Jefferies Global Healthcare Conference in London on November 16 and 17, respectively. Additionally, members from our management team will participate in a fireside chat in one-on-one meetings at the 45th Annual JPMorgan Healthcare Conference in San Francisco in January of next year.

Our scientific commercial and medical affairs teams will be President present at phenomenal Hope 2026 on December 4 in Boston and at the Pulmonary Vascular Research Institute Annual Congress in Bangkok in late January of next year. Now I will turn the webcast over to Martine for an overview of our development pipeline and business activities. Martine?

Martine Rothblatt

Thank you, Harry, and good morning, everyone. We have slides available for reference, and I encourage you to review those at your leisure. I'm not going to speak directly to the slides. As we look back on the third quarter, I'm incredibly proud of what our teams have accomplished. .

We executed at a high level across our business and across our company, delivering for patients while advancing one of the most ambitious growth strategies in biotechnology. The significance of this quarter extends beyond any individual results or milestone. It reflects the broader transformation underway at United Therapeutics as we build a comprehensive cardiopulmonary and respiratory medicine franchise capable of reaching dramatically more patients than ever before.

For most of our history, UT has been known as a pulmonary hypertension company. Today, that legacy serves as the foundation for a much bigger UT. Over the next several years, we expect to introduce wave after wave of innovation across multiple therapeutic and device platforms. From nebulized and dry powder therapies to softness inhalers, once-daily medicines and combination products.

We have 14 programs in development. Together, these advances are intended to address some of the largest unmet needs in pulmonary fibrosis and pulmonary hypertension. We are building an integrated portfolio designed around the needs of individual patients.

Our strategy is to keep innovating, so we can offer more patients the right therapy in the right format at the right time. The scale of that opportunity extends far beyond our historic pulmonary hypertension market across IPS, PPS and PH-COPD alone, we are pursuing patient populations totaling approximately 1 million people in the United States. Supporting this strategy are significant and durable competitive advantages.

Our portfolio features extensive intellectual property protections, including fibrosis-related patents, device protections and composition of matter protection for ralinepag, many of which extend into the 2040s, just as important, our market advantages include decades of expertise, extensive engagement with physicians, specialized commercialization capabilities manufacturing investments and a proven ability to bring complex drug device combinations to market.

We are building on our strength through the philosophy that has guided us for years, approve, then improve. We first established a therapy as quickly as possible because our patients do not have time. Then we continue to enhance convenience, administration and treatment experience through new devices, formulations and next-generation medicines. This disciplined approach creates a pipeline in which every new product builds on the foundation established by the last and provides improvements for the next.

And as compelling as our cardiopulmonary and respiratory franchises are they represent only 1 pillar of our long-term vision. In parallel, we continue to advance our manufactured organ alternatives programs and build the infrastructure we need to address one of medicine's greatest unmet needs. We believe this platform has the potential to revolutionize transplantation over the next decade, just as our therapies have revolutionized pulmonary hypertension over the past 2 decades.

When I step back, I see a United Therapeutics stronger than at any point in our history with a growing commercial business, late-stage assets of significant potential multiple upcoming launches and a clear strategy for creating value over the long term. In closing, thank you to our fellow Unitarians, patients, physicians, shareholders and our other stakeholders for helping us fulfill our purpose. And with that, I'll turn the call over to our President, Michael Benkowitz, for an overview of our commercial performance for the quarter. Mike?

Michael Benkowitz

Thanks, Martine, and good morning, everybody. For the third quarter of 2026, we delivered record total revenue of $833 million and record Tyvaso revenue of $504 million. Highlighted by strong sequential growth and underlying demand. 3 months ago, I said confidence is earned through execution, not projections.

This quarter's results are best quarter ever demonstrate that execution and reinforce our conviction that our business has regained meaningful momentum. A huge shout out to all of our commercial, commercial operations and medical teams for their hard work, persistence and performance.

Tyvaso's performance was driven by strong underlying demand as the patient metrics we highlighted last quarter translated into commercial results. Starts, referrals, patient demand, increased dosing and physician engagement all continue to support growth and emphasize the value of differentiated products, disciplined execution, a clear understanding of physician and patient needs and our expertise and support in the field of pulmonary hypertension.

Most importantly, we see meaningful room to grow from here. The investments we made earlier this year in resources and sharpening our messaging are working as intended by expanding our reach deepening physician engagement, increasing disease awareness and driving greater penetration across PAH and PH ILD. We have greater conviction in our strategy than ever. Elsewhere, the recent court decision upholding our intellectual property, together with the settlement we reach, provide important clarity and reinforce the long-term durability of our base business.

The terms of our settlement were highly favorable for United Therapeutics, ultimately removing PH-ILD from the tropo label, preventing its promotion and marketing into that indication and prohibiting Liquidia from encouraging off-label usage, which we will be monitoring very closely. With no direct branded competition on the horizon, we can remain focused on growing the large underpenetrated PH-ILD market.

Based upon the provisions contemplated in the settlement and damages structure, near-term expectations for transitions from UTP to Tyvaso should be moderate. The larger opportunity in PH-ILD continues to remain focused on expanding physician awareness, identifying more eligible patients and growing new prescriptions.

That gives Tyvaso a long runway for largely uncontested growth. Step back, our story is not about stabilizing our business. It is about building on renewed momentum from our durable commercial foundation with 2 of the most important potential launches in our street still ahead. Once approved, we expect nebulized Tyvaso and IPF and ralinepag in PAH will each address significant unmet need. Both are supported by compelling clinical data and both have the potential to become multibillion-dollar growth drivers for United Therapeutics.

These opportunities do not replace our current growth story, they accelerate it. In closing, our base business is performing. Our commercial strategy is working. Our competitive position is strong and we expect to enter 2027 with substantially more momentum than we had entering 2026.

To highlight this continued momentum, we received over 1,000 referrals for a UT product in October, the most ever received in a single month. We remain focused, accountable and committed to continue delivering compelling results. And as proud as we are of this quarter, we believe we are just getting the full scale of what we are determined to achieve. And with that, I'll pass the call back to Harry to run the Q&A.

Harrison Silvers

Thanks, Michael. Thanks, Martine. Great updates from both of you. [Operator Instructions] Operator, you can start.

Operator

[Operator Instructions] Your first question comes from Joseph Thome with TD Hain.

分析師問答

Joseph Thome

Maybe could you talk a little bit more about the patient switch dynamic now that PHLD will be off-label for you [indiscernible] , what are sort of your expectations of current patients switching over? And maybe for new start markets, you mentioned that you are monitoring their off-label use potential. Can you just kind of go into how you're doing that in the field. .

Unknown Executive

Thanks for the question, Joe. I'm going to pass this 1 to Michael.

Michael Benkowitz

Sure. Yes. So Joe, thanks for the question. On the patient switch is the -- per the terms of the settlement agreement, we sort of contemplated -- we didn't -- there was no requirement or expectation that patients would have to switch from [indiscernible] to Tyvaso DPI and so we kind of contemplated that in the damage structure, as I mentioned.

And so I think, obviously, we're going to continue to talk about the benefits the differentiation of DP relative to Trebia, but it's really going to be, I think, a physician patencies to whether or not they want to transition existing patients over to Titaso-DPI. But that's not something that's going to be required for the terms of the settlement.

So like I said, I think what you're going to see is if you've got patients on Metropia that for are having issues, obviously, Tyvaso remains an option, you can switch, but there's not -- I think if a patient's doing well on. There's not really going to be, I think, a push on the part of doctors to switch patients over. So as I said, the real opportunity here is with new prescriptions and continuing to penetrate the pH ILD market, which we're starting to see with the benefit of the expanded sales force.

In terms of monitoring that, I mean, look, we kind of -- I'm not going to really get into kind of sources and methods of how we're going to do that. But I think we have pretty good visibility into how things are playing out in terms of prescriptions and indications, and we're just going to continue to kind of keep an eye on that and see how that plays out along with what we're hearing in the market through our interactions with physicians.

Harrison Silvers

Thanks, Michael. Operator next question.

Operator

Your next question comes from the line of Olivia Brayer with Cantor.

Olivia Brayer

Michael, I just quickly wanted to follow-up on PHLD. Are you guys actually seeing any acceleration in new starts on Tyvaso in the fourth quarter just on the back of that settlement? Or do you really expect that to become more meaningful as patients come up for reauthorization in January? Just trying to kind of reconcile your comments around October trends. And then I'm sorry, Harry, -- but my real question is on the softness inhaler program, where are you guys in the submission process at this point? And is a filing still on track for the end of the year? And then as you think about softness kind of looking ahead to PH-COPD, what have you guys actually seen in the SMI product profile that's giving you so much confidence that it could succeed in this patient population, just given some of the challenges that we've already -- or that others have experienced, right, with prior approaches?

Harrison Silvers

Sound more like 3. I'll give Michael the first question. And then if you could pass it to Pat on the NDA expectations for SMI and then perhaps we can close it off with expectations in PH COP.

Michael Benkowitz

Yes. Olivia, you never disappoint with your multi question. So on PLD, so if you kind of think about the time line of everything, as I said, I think even before the settlement, right, going back to like mid-September, I think we saw this inflection in the referrals coming in. Really across both cations, PAH and PLD for Tyvaso that has persisted through the end of October into November, in terms of working out the litigation decision, the settlement, I mean, all of that stuff really didn't really get worked out until, I guess, what was that second, third week of October.

So still a little early to see I think another sort of inflection in terms of PH ILD. I would expect that we're going to start to see that here over the next couple of weeks. And into December than obviously the first part of the year. So that's kind of where things are right now. I mean we do expect to see that I've seen -- I kind of monitor the daily referral trends. We have a couple of days where we spiked, but I expect us to see kind of a new baseline in terms of referrals here over the next few weeks. Pat, do you want to take the other question?

Patrick Poisson

We recently met with the FDA to discuss our NDA filing strategy, and that was preplanned. And following that discussion, we've now determined that additional work is going to be needed to support the application. So as a result of that, we now expect to submit the NDA in 2027 and not at the end of this year. We are actively working with our development partner to complete the necessary activities and establish an updated filing time line. Leigh pass it on to you.

Leigh Peterson

Yes. As far as PH-COPD, goes, our Phase II trial, as you know, we have IND clearance for that study. And in terms of the biological rationale for COPD, mean the pharmacology of inhaled treprostinil is really well characterized with our commercially approved treatments for PH and PH-ILD.

And as you know, in these patients with [indiscernible] with group through PH, such as ILD and COPD, the inhaled treprostinil directly targets more ventilated portions of the lungs. And so that can minimize the VQ mismatch that's with the concern with more systemic therapies that are also vasodilators.

So it's really important to note that not only do we have a more robust design in our study. But we've really, really looked very carefully at the patient population that was enrolled into the prior study, COPD study and really worked hard with our steering committees to enrich this current population through the inclusion exclusion criteria to improve the chances of success as well as just decrease the risk of this program.

Harrison Silvers

Thanks, Lee. That was a great overview by all 3 of you.

Operator

Your next question comes from the line of Ash Verma with UBS.

Ashwani Verma

So on ralinepag, I wanted to ask about this open action indicated that you have mentioned in the Q about this API manufacturer. Can you talk about what is the contingency plan ahead of the potential regulatory approval for this?

Harrison Silvers

Thanks for the question, Ash. Pat, we'll kick that over to you.

Patrick Poisson

Yes. Thanks, Ash. So as you saw in the Q, our API supplier has an OAI compliance status as the result of an inspection earlier this year. We're actively working with them to remediate their compliance status so that it doesn't impact our PDUFA date. So that's kind of priority one.

We do have some alternative plans that are progressing in parallel. But on a positive note, they've recently provided FDA updated information on their corrective actions. And there's open dialogue between the parties. So we remain hopeful that this will get resolved fairly quickly, but we do have contingency plans in place.

Harrison Silvers

Great. Thanks, Pat. .

Operator

Your next question comes from the line of Roger Song with Jefferies.

Jiale Song

Great. Maybe related to the triplet oral pill, since the bioequivalent study is not sufficient for filing. So what is the current plan for development and funding plan for the [indiscernible]

Harrison Silvers

Thanks for your question, Roger. Pat, can I ask you to answer this 1 again?

Patrick Poisson

Yes. So we had a discussion with FDA and they share that, that was their feedback to us. And so right now, we're looking at what our options are really, if there's an alternate path that they would accept that's going to take us a little while. So -- but right now, we're just treading water. And while we work on different options that we can present to them. .

Operator

Your next question comes from the line of Rowan Ruiz with Leerink Partners. .

Unknown Analyst

A quick question. Could you elaborate on the -- what you saw as the biggest drivers behind the Tevas strength in the quarter? And if any could increase into year-end? I'm specifically focused on if there is more traction from the upsized field force or any inventory or seasonal dynamics that we should consider in addition to underlying demand growth?

Harrison Silvers

For your question. This 1 will go to Michael.

Michael Benkowitz

Sure. Yes, thanks for the question. So no inventory or seasonal dynamics really, I think, played into the quarter. I think it's really kind of a multifactorial thing. One is just honestly, just great execution by the sales team. I think we've like we talked about in the last quarter came out of the quarter with really strong momentum. .

We've been able to maintain that through -- even through October, as I talked about earlier. I think as we've talked about on prior calls, I think some of the challenges we faced in the prior quarters are we'd have 2 really good months and 1 soft month and the 2 good months weren't enough to offset the soft mine. So we've been kind of flat for several quarters. But now we've got, I think, really consistent performance month to month to month. And so we're stocking good months on top of good months. And so that's really just, I think, plays into really strong execution by our commercial teams.

I think the other thing that we've seen is at the beginning of the year, we -- we introduced a 80-microgram cartridge. So one breath gives you the equivalent of 15 nebulized breath and then some higher dose kits. I think there's been this misinformation out there that you can't get to higher doses on Tyvaso DPI. I think we've effectively debunk that for patients that have started on Tyvaso DPI since we introduced those cartrids.

We introduced those higher strength kids, like 1 in 3 patients are, have achieved these higher doses which is twice what it was beforehand. So that certainly, I think, played into the performance is that we're getting patients to higher dose which helps from a revenue standpoint, but also helps from a retention standpoint because patients are obviously benefiting from the product.

I think in terms of the effect of the sales force expansion. I think in terms of region frequency, that played a role in some of the consistent performance month-to-month. But in terms of like what we've seen in terms of increase in referrals increase in starts. I think we -- as I said, we start to see kind of this inflection point, probably mid-September. As a result of that. So that didn't really you can't really -- I don't think you can draw a straight line through to the revenue line for Q3. I think we'll start to see the benefit of that here in Q4 and then into next year. But it's clear that the expansion is working, and we're seeing the benefit of that. But probably limited revenue impact of that in Q3, but we certainly expect to see that, like I said, this quarter and heading into next year.

Harrison Silvers

Great color.

Operator

Our next question comes from the line of Jessica Fye with JPMorgan.

Jessica Fye

Congrats on the quarter. a quick follow-up. I think it was 1 of Olivia's questions. Pat, can you just expand on what was new that's needed for the softness filing?

Patrick Poisson

Yes. It's not necessarily anything new. It's just additional data in some areas that we need to provide. So really -- it's really just that. It wasn't anything you've asked us to do in addition to what we had already planned.

Jessica Fye

So [indiscernible] versus generating more data.

Patrick Poisson

It's just generating additional data. And I don't think we're particularly worried about it. It's just a lead time to do it. .

Harrison Silvers

Great. Thanks, Jess, for the question and Pat for the answer.

Operator

Your next question comes from the line of Ben Burnett with Wells Fargo.

Benjamin Burnett

I want to ask about ralinepag and just what was behind the decision to buy out Arena's economics to ralinepag. And I guess how did you value that transaction?

Harrison Silvers

Thanks for the question, Ben. I'm going to pass this 1 to James. .

James Edgemond

Yes. Thanks, Harry. Ben, overall, this transaction to buy down the royalty demonstrates really our confidence in the revenue opportunity for oral ralinepag which, as you know, has a pending new drug application under review by the FDA for pulmonary arterial hypertension, which you know is a PDUFA date of June 24 of next year. .

But in addition, the reason why we pursue this opportunity is we have conviction in the new dry powder inhalation formulations that we're developing for a variety of pulmonary indications going forward. And I would say the price was the result of really extensive negotiations, and we're not going to get into the details regarding that. But we looked at this more as an opportunistic use of capital kind of in our overall capital allocation waterfall. So thanks for the question.

Harrison Silvers

Thanks for that, James. Operator, we have time for 1 more question. Go ahead.

Operator

And that question is going to come from the line of Lisa Walter at RBC.

Lisa Walter

Congrats on a strong quarter. Maybe another 1 on ralinepag, DPI. Curious as plans have changed around developing this for PAA -- or is PH still part of the plan, along with PH-ILD, IPS and PPS? And how are you thinking about the clinical development plan for ralinepag DPI in these indications? Any color here would be helpful.

Harrison Silvers

Yes, absolutely. Good to hear your voice, Lisa. I'm going to pass this 1 over to Leigh to provide some color.

Leigh Peterson

Yes. Thanks for the question. So we are in the process, as you know, of conducting the IND-enabling studies as well as planning for the Phase I study in healthy volunteers. Now that Phase I study prestudy safety. That will actually inform any other registrational study that we want to do. So we're initially planning on doing a PH-ILD study and they're very, very soon thereafter or essentially at the same time, seeking approval for IPF, PPF, all of those will require some pivotal studies assessing the safety and efficacy.

But again, we're confident that the mechanism, both of the very, very potent drug, self the ralinepag being a very, very potent IP receptor agonist as well as the inhaled route for these indications where there's either some fibrosis or later for COPD, but that's not in the immediate plan. But anyway, this inhaled route to minimize VQ mismatch is really probably will make what we're calling route pie, a very transformative product in these larger indications.

Harrison Silvers

Excellent overview, Lee, and that will conclude the Q&A. So I'll pass it back to the operator to close this out. .

Operator

Thank you for participating in today's United Therapeutics Corporation's earnings webcast. A rebroadcast of this webcast will be available for replay for 1 week by visiting the Events and Presentations section of the United Therapeutics Investor Relations our website at ir.unither.com. This now concludes today's call, and you may now disconnect.